NASH and Coronary Disease

Non-Alcoholic Fatty Liver Disease Clinical Trial

— CORO-NASH  

Official title:

Prevalence and Impact of NAFLD in Patients With Symptomatic Coronary Artery Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03819283
• Other study ID #: APHP180013
• Secondary ID: 2018-A01752-53
• Status: Recruiting
• Phase: N/A
• Start date: April 19, 2019
• Est. completion date: July 19, 2024

Study information

• Verified date: March 2022
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Gérard HELFT, PU-PH
• Phone: 0142162911
• Email: gerard.helft[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although the clinical relationship between NAFLD/NASH and cardiovascular (CV) risk is now well established, there is very little awareness of the hepatic disease and the way it may contribute to increased CV risk in patients seen in cardiology clinics for complications of coronary artery disease. Our clinical hypothesis is that NAFLD, possibly at a stage of advanced fibrosis, is common in patients with symptomatic coronary artery disease (CAD) and increases the risk of severe atherosclerotic lesions. The primary aim of this study is to determine (a) the prevalence and (b) the severity spectrum of NAFLD among patients with symptomatic coronary artery disease. The secondary aims are: to analyze the impact of the presence and the severity spectrum of NAFLD (steatosis, steatohepatitis and fibrosis) on the severity of CAD ; To determine the profile of NAFLD patients at risk to develop coronary lesions; To explore the mechanistic link between NAFLD and CAD beyond common metabolic risk factors.

Description:

Because of shared metabolic risk factors and pathogenic pathways (insulin resistance, chronic low grade inflammation, atherogenic dyslipidemia) non-alcoholic fatty liver disease is frequently associated with cardiovascular (CV) disease. Despite a lot of transversal studies showing a frequent association between NAFLD and CV disease, it is difficult to determine if NAFLD plays an active role in atherogenesis or is just a marker of common risk factors. Some longitudinal studies, although retrospectives, showed that NAFLD favors the progression of early atherosclerosis, suggesting that NAFLD is an independent CV risk factor beyond the association driven by metabolic syndrome.

Although the clinical relationship between NAFLD/NASH and CV risk is now well established, there is very little awareness of the hepatic disease and the way it may contribute to increased CV risk in patients seen in cardiology clinics for complications of coronary artery disease (CAD). Our clinical hypothesis is that NAFLD, possibly at a stage of advanced fibrosis, is common in patients with symptomatic CAD and increases the risk of severe atherosclerotic lesions.

The primary aim of this study is to determine (a) the prevalence of NAFLD among patients with symptomatic CAD.

The secondary aims are:

• To determine the severity spectrum of NAFLD among patients with coronary artery disease.

• To analyze the impact of the presence and the severity spectrum of NAFLD (steatosis, steatohepatitis and fibrosis) on the severity of CAD and long term clinical outcomes (ancillary studies)

• To determine the clinical profile of NAFLD patients at risk to develop coronary lesions

• To explore the mechanistic link between NAFLD and CAD beyond common metabolic risk factors.

• Establish a cohort of patients with NAFLD and coronary disease allowing future subsequent ancillary studies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: July 19, 2024
• Est. primary completion date: July 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (>18 years old) that undergo coronary angiography for suspected CAD for: acute coronary syndrome (ACS) with ST-elevation ACS (STE-ACS) or non-ST elevation (NSTE-ACS) with or without troponin elevation OR suspicion of stable coronary artery disease after stress imaging techniques and/or symptoms of angina.

• Patients with one or more of traditional cardiovascular risk factors.

Exclusion Criteria:

• Patients unable to sign the informed consent

• Morbidly obese patients (BMI > 40kg/m2)

• Excessive alcohol consumption of more than 50 g/day

• Patients with known other causes of chronic liver disease (viral hepatitis, autoimmune, hemochromatosis...)

• Active neoplastic pathology

• Pregnant or breastfeeding women

• Protected adults

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease

Intervention

Diagnostic Test:
• Hepatic evaluation
Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)

Locations

Country	Name	City	State
France	Pitié Salpêtrière Hospital	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Institute of Cardiometabolism and Nutrition, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NAFLD and significant fibrosis (= F2)	NAFLD will be defined by the presence of steatosis at ultrasound concomitant with at least one metabolic risk factor among overweight/obesity, type 2 diabetes, dyslipidemia. The severity of NAFLD will be determined by the presence of significant fibrosis (=F2) by noninvasive measures (either serum markers or transient elastography).	Visit 2
Secondary	Severity of the coronary lesions	Based on the results of the coronary angiography, patients will be classified according to the severity of CAD as follows: no CAD, stable CAD (less than 50% stenosis, 1 vessel CAD with > 50% stenosis, 2 vessels CAD with > 50% stenosis, 3 vessels CAD with > 50% stenosis), and acute coronary syndrome.	Visit 1
Secondary	Correlation between the histological severity of NAFLD and the severity of coronary lesions	The severity of the coronary lesions will be defined as follows : absent, stable coronary lesions (significant >=50% or non significant coronary atheroma), acute coronary syndrome	51 months after the start of the study
Secondary	Analyse of clinical factors associated with the severity of coronary lesions according to the presence or absence of NAFLD	The severity of the coronary lesions will be defined as follows : absent, stable coronary lesions (significant >= 50% or non significant coronary atheroma), acute coronary syndrome	51 months after the start of the study
Secondary	Analyse of the metabolomic signature associated with the severity of coronary lesions according to the presence and severity of NAFLD	The severity of the coronary lesions will be defined as follows : absent, stable coronary lesions (significant >=50%or non significant coronary atheroma), acute coronary syndrome	Visit 1 and 2